A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations

NCT06947811 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

71

Enrollment

OTHER

Sponsor class

Conditions

EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor

Interventions

DRUG: Almonertinib
DRUG: Palbociclib

Sponsor

Sun Yat-sen University